Literature DB >> 7190399

3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile.

T Ito, M Hori, Y Masuda, K Yoshida, M Shimizu.   

Abstract

Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-180) were examined electroencephalographically (EEG) on seizure activities induced by several means in rats and cats. AD-810 depressed the cortical focal seizure induced by electrical stimulation of the visual cortex at doses ineffective against the thalamic and hippocampal after-discharges in cats. AD-810 suppressed both interictal spikes and secondary generalized seizures (SGS), induced by cortical application of tungstic acid gel, in intact and decerebrated rats. Suppression of the spikes and SGS by AD-810 was also observed in cats with the epileptogenic foci produced by cortical freezing. Neither spontaneous EEG pattern nor EEG arousal response was modified with AD-810. It is suggested that AD-810 supresses the epileptogenic focus activity in the cortex and blocks the seizure propagation from the cortex to the subcortical structures through the effects on the cortex.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7190399

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

Review 1.  Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 2.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.